The annualized cost to respondents is estimated at $68,000. Capital Costs are $0. Operating Cost is roughly $15,000 for the database to accept and coordinate responses.

Request For Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. John McKew, Chief, Preclinical Development Branch, NIH Center for Translational Therapeutics, 9800 Medical Center Drive, Building B, Rockville, MD 20850.

Comments Due Date: Comments regarding this information collection are hereby given of the following meeting.

Dated: November 1, 2011.

John McKew,
Chief, Preclinical Development Branch, NIH Center for Translational Therapeutics, National Human Genome Research Institute, National Institutes of Health.

[FR Doc. 2011–28958 Filed 11–8–11; 8:45 am] BILLYING CODE 4140–01–P

---

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Gap Junctions: Program Project Grant Review.

Date: December 6–7, 2011.

Time: 8 a.m. to 11 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Peter B Guthrie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142, MSC 7581, Bethesda, MD 20892, (301) 435–1239, guthriep@csr.nih.gov.

Name of Committee: Biology of Development and Aging Integrated Review Group, International and Cooperative Projects—1 Study Section.

Date: December 13, 2011.

Time: 12 p.m. to 7 p.m.

Agenda: To review and evaluate grant applications.

Place: Westin Grand, 2350 M Street, NW, Washington, DC 20037.

Contact Person: Hillary D Signon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5222, MSC 7582, Bethesda, MD 20892, (301) 594–6377, sigmonhl@csr.nih.gov.


Dated: November 2, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–28958 Filed 11–8–11; 8:45 am] BILLYING CODE 4140–01–P

---

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology.

Date: November 29, 2011.

Time: 8 a.m. to 7 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Savvas C Makrides, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6161 Executive Blvd., Rm 8053, Bethesda, MD 20892, (301) 594–1279, makridessc@mail.nih.gov.

Information is also available on the Institute’s/Center’s home page: http://deainfo.nci.nih.gov/advisory/sep/sep.htm, where an agenda and any additional